Psoriasis

Weight-loss interventions significantly enhance psoriasis severity and quality of life, emphasizing their role in effective psoriasis management strategies.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

Genetic predisposition to psoriasis appears to raise depression risk, offering insights into shared inflammatory mechanisms and implications for screening.

Topical roflumilast 0.3% improved IGA, PASI, itch, and symptom scores in plaque psoriasis with a safety profile comparable to vehicle.

FDA reviews roflumilast cream for young children with plaque psoriasis, potentially offering a first-of-its-kind topical treatment option.

Your daily dose of the clinical news you may have missed.

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

Your daily dose of the clinical news you may have missed.

The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.

Publication of the phase 3 ARRECTOR trial findings precede an anticipated PDUFA date of May 22, 2025, for the investigational foam, now under FDA review.

The April issue covers atopic dermatitis, highlighting primary care’s role in early diagnosis, key updates from recent conferences, and more.

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.